🔗 Share this article

As America continues making sweeping revisions to its immunization guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports physician and epidemiologist who first made her name by questioning COVID-19 shots in the global health crisis and has focused upon possible fatalities after Covid vaccination in her short tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Public health authorities had intended to unveil radical revisions to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, it is understood – a substantial departure that would put the US out of alignment with much of the world with little proof for improved outcomes. This reveal has been postponed until the next year.

In place of the director of the vaccine center, Høeg is listed to speak at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to head the center this calendar year.

A Shift at the FDA

This interim role may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric immunization guidelines in the US so as to align more like Denmark, a nation with nationalized medicine and a citizenry about the population of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has little discernible experience in drug development, regulation or leadership, which has been customary for former leaders of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and CBER since March.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a large organization. She has no expertise in drug approvals.”

Past directors of the center would “grasp legal statutes and the science of drug development”, said a former acting FDA commissioner. “Frankly, she doesn’t have the type of experience that former directors who headed the center have had.”

This division has an immense workload at the FDA, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the off-patent medication office clears thousands of generic medications. There is also a biosimilars division, over-the-counter program and more, and every single one have to be looked after,” Dr. Woodcock explained. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major management element to the role, which oversees more than 5,000 employees. “It’s a massive leadership role, if you do it right,” she concluded.

Agency Reaction and Disputed Initiatives

In response to inquiries about Høeg’s qualifications and whether this appointment signifies increased cooperation among regulatory chiefs on vaccines, a press secretary said that the “concerns stem from flawed presumptions”.

“This background is consistent with the functions of her position,” the official stated, pointing to the months Høeg spent counseling the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg inherits the agency head's controversial fast-track approval initiative, a contentious expedited drug-approval program that reportedly concerned her preceding directors. “How are these therapies being selected for this fast-track system? Who makes the decisions?” Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the agency seems to be moving towards less stringent regulations of all drugs, with the exception of immunizations.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if problematic, history, critics said. She published a study using unconfirmed volunteer-provided data to determine the frequency of heart inflammation after Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Included in her “desired changes” for the new federal leadership featured changing guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked post-election on a audio program. At the agency, Dr. Høeg has reportedly suggested barring young men from obtaining COVID-19 vaccinations.

“She’s an all-around true believer who begins with her conclusions and works backwards to fit the science in a highly deceptive, fraudulent fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|